{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:20:31Z","timestamp":1759566031418,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate overall survival and locoregional recurrence between patients with invasive breast tumours and sentinel node metastasis undergoing sentinel lymph node dissection (SLND) alone and those undergoing complete axillary lymph node dissection (ALND). In this retrospective cohort study, we reviewed the medical records of patients with invasive breast carcinoma who underwent lumpectomy at a public university hospital in Brazil between 2008 and 2018. We evaluated the overall survival and the locoregional recurrence using Kaplan\u2013Meier and Cox regression analyses, respectively. Overall, 97 participants who underwent lumpectomy were enroled; 41 in the ALND group, and 56 in the SLND group, according to Z0011 criteria. Only 17% of the patients in the ALND group had an additional biopsy-proven axillary disease, and 83% were treated with complete dissection unnecessarily. The 5-year survival rates were 80.1% and 87.5% for SLND and ALND, respectively (p\u2009=\u20090.376). Locoregional recurrence was rare (1.7% and 7.3% in the SLND and ALND, respectively; p\u2009=\u20090.3075). Overall survival and locoregional recurrence were similar between the two groups. The de-escalation of ALND to SLND in women with metastasis in the sentinel lymph node treated with conservative surgery and radiotherapy that meet the Z0011 criteria is feasible even in developing countries.<\/jats:p>","DOI":"10.1038\/s41598-021-99359-w","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:10:54Z","timestamp":1633651854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Survival and recurrence with or without axillary dissection in patients with invasive breast cancer and sentinel node metastasis"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3116-3550","authenticated-orcid":false,"given":"Vanessa Monteiro","family":"Sanvido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-0717","authenticated-orcid":false,"given":"Simone","family":"Elias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1418-0295","authenticated-orcid":false,"given":"Gil","family":"Facina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-6580","authenticated-orcid":false,"given":"Silvio Eduardo","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0601-4388","authenticated-orcid":false,"given":"Afonso Celso Pinto","family":"Naz\u00e1rio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"99359_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul; 70(4):313]. CA Cancer J. Clin. 68, 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"99359_CR2","doi-asserted-by":"publisher","first-page":"e028461","DOI":"10.1136\/bmjopen-2018-028461","volume":"9","author":"K Hu","year":"2019","unstructured":"Hu, K. et al. Global patterns and trends in the breast cancer incidence and mortality according to sociodemographic indices: An observational study based on the global burden of diseases. BMJ Open 9, e028461. https:\/\/doi.org\/10.1136\/bmjopen-2018-028461 (2019).","journal-title":"BMJ Open"},{"key":"99359_CR3","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1016\/S2214-109X(20)30215-1","volume":"8","author":"E Heer","year":"2020","unstructured":"Heer, E. et al. Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study. Lancet Glob. Health. 8, e1027\u2013e1037. https:\/\/doi.org\/10.1016\/S2214-109X(20)30215-1 (2020).","journal-title":"Lancet Glob. Health."},{"key":"99359_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-017-4490-3","volume":"167","author":"MS Dreyer","year":"2018","unstructured":"Dreyer, M. S., Nattinger, A. B., McGinley, E. L. & Pezzin, L. E. Socioeconomic status and breast cancer treatment. Breast Cancer Res. Treat. 167, 1\u20138. https:\/\/doi.org\/10.1007\/s10549-017-4490-3 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"99359_CR5","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1200\/JCO.2000.18.13.2553","volume":"18","author":"AE Giuliano","year":"2000","unstructured":"Giuliano, A. E. et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer [published correction appears in J Clin Oncol 2000 Nov 15;18(22):3877]. J. Clin. Oncol. 18, 2553\u20132559. https:\/\/doi.org\/10.1200\/JCO.2000.18.13.2553 (2000).","journal-title":"J. Clin. Oncol."},{"key":"99359_CR6","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1245\/s10434-012-2531-z","volume":"19","author":"AS Caudle","year":"2012","unstructured":"Caudle, A. S. et al. American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on surgeon practice patterns. Ann. Surg. Oncol. 19, 3144\u20133151. https:\/\/doi.org\/10.1245\/s10434-012-2531-z (2012).","journal-title":"Ann. Surg. Oncol."},{"key":"99359_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.clbc.2017.10.007","volume":"18","author":"A Weiss","year":"2018","unstructured":"Weiss, A. et al. Expanding implementation of ACOSOG Z0011 in surgeon practice. Clin. Breast Cancer. 18, 276\u2013281. https:\/\/doi.org\/10.1016\/j.clbc.2017.10.007 (2018).","journal-title":"Clin. Breast Cancer."},{"key":"99359_CR8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.amjsurg.2014.08.009","volume":"208","author":"KA Robinson","year":"2014","unstructured":"Robinson, K. A., Pockaj, B. A., Wasif, N., Kaufman, K. & Gray, R. J. Have the American College of Surgeons Oncology Group Z0011 trial results influenced the number of lymph nodes removed during sentinel lymph node dissection?. Am. J. Surg. 208, 1060\u20131064. https:\/\/doi.org\/10.1016\/j.amjsurg.2014.08.009 (2014).","journal-title":"Am. J. Surg."},{"key":"99359_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jamcollsurg.2015.02.035","volume":"221","author":"K Yao","year":"2015","unstructured":"Yao, K. et al. Impact of the American College of Surgeons Oncology Group Z0011 randomized trial on the number of axillary nodes removed for patients with early-stage breast cancer. J. Am. Coll. Surg. 221, 71\u201381. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2015.02.035 (2015).","journal-title":"J. Am. Coll. Surg."},{"key":"99359_CR10","doi-asserted-by":"publisher","first-page":"e477","DOI":"10.1016\/j.clbc.2017.09.001","volume":"18","author":"JM Mann","year":"2018","unstructured":"Mann, J. M., Wu, X., Christos, P. & Nagar, H. The state of surgical axillary management and adjuvant radiotherapy for early-stage invasive breast cancer in the modern era. Clin. Breast Cancer. 18, e477\u2013e493. https:\/\/doi.org\/10.1016\/j.clbc.2017.09.001 (2018).","journal-title":"Clin. Breast Cancer."},{"key":"99359_CR11","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1245\/s10434-016-5310-4","volume":"23","author":"MW Tsao","year":"2016","unstructured":"Tsao, M. W. et al. A population-based study of the effects of a regional guideline for completion axillary lymph node dissection on axillary surgery in patients with breast cancer. Ann. Surg. Oncol. 23, 3354\u20133364. https:\/\/doi.org\/10.1245\/s10434-016-5310-4 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"99359_CR12","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","volume":"25","author":"A Lucci","year":"2007","unstructured":"Lucci, A. et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J. Clin. Oncol. 25, 3657\u20133663. https:\/\/doi.org\/10.1200\/JCO.2006.07.4062 (2007).","journal-title":"J. Clin. Oncol."},{"key":"99359_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jnci\/djj158","volume":"98","author":"RE Mansel","year":"2006","unstructured":"Mansel, R. E. et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial [published correction appears in J Natl Cancer Inst. Jun 21;98(12):876]. J. Natl. Cancer Inst. 98, 599\u2013609. https:\/\/doi.org\/10.1093\/jnci\/djj158 (2006).","journal-title":"J. Natl. Cancer Inst."},{"key":"99359_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.21535","volume":"102","author":"T Ashikaga","year":"2010","unstructured":"Ashikaga, T. et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J. Surg. Oncol. 102, 111\u2013118. https:\/\/doi.org\/10.1002\/jso.21535 (2010).","journal-title":"J. Surg. Oncol."},{"key":"99359_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano, A. E. et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 305, 569\u2013575. https:\/\/doi.org\/10.1001\/jama.2011.90 (2011).","journal-title":"JAMA"},{"key":"99359_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","volume":"252","author":"AE Giuliano","year":"2010","unstructured":"Giuliano, A. E. et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial. Ann. Surg. 252, 426\u2013433. https:\/\/doi.org\/10.1097\/SLA.0b013e3181f08f32 (2010).","journal-title":"Ann. Surg."},{"key":"99359_CR17","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano, A. E. et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318, 918\u2013926. https:\/\/doi.org\/10.1001\/jama.2017.11470 (2017).","journal-title":"JAMA"},{"key":"99359_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"AE Giuliano","year":"2016","unstructured":"Giuliano, A. E. et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann. Surg. 264, 413\u2013420. https:\/\/doi.org\/10.1097\/SLA.0000000000001863 (2016).","journal-title":"Ann. Surg."},{"key":"99359_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa020128","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher, B. et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N. Engl. J. Med. 347, 567\u2013575. https:\/\/doi.org\/10.1056\/NEJMoa020128 (2002).","journal-title":"N. Engl. J. Med."},{"key":"99359_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti, V. et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial [published correction appears in Lancet Oncol. Jun; 14(7):e254]. Lancet Oncol. 14, 297\u2013305. https:\/\/doi.org\/10.1016\/S1470-2045(13)70035-4 (2013).","journal-title":"Lancet Oncol."},{"key":"99359_CR21","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker, M. et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 15, 1303\u20131310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7 (2014).","journal-title":"Lancet Oncol."},{"key":"99359_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.breast.2013.02.001","volume":"22","author":"W Gatzemeier","year":"2013","unstructured":"Gatzemeier, W. & Mann, G. B. Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND)-ACOSOG Z0011 results and beyond. Breast 22, 211\u2013216. https:\/\/doi.org\/10.1016\/j.breast.2013.02.001 (2013).","journal-title":"Breast"},{"key":"99359_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.breast.2019.01.008","volume":"44","author":"SD Simon","year":"2019","unstructured":"Simon, S. D. et al. Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. Breast 44, 113\u2013119. https:\/\/doi.org\/10.1016\/j.breast.2019.01.008 (2019).","journal-title":"Breast"},{"key":"99359_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani, C. et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391, 1023\u20131075. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3 (2018).","journal-title":"Lancet"},{"key":"99359_CR25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1245\/aso.2003.03.015","volume":"10","author":"KJ Van Zee","year":"2003","unstructured":"Van Zee, K. J. et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann. Surg. Oncol. 10, 1140\u20131151. https:\/\/doi.org\/10.1245\/aso.2003.03.015 (2003).","journal-title":"Ann. Surg. Oncol."},{"key":"99359_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/SLA.0b013e318238f461","volume":"255","author":"EA Mittendorf","year":"2012","unstructured":"Mittendorf, E. A. et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann. Surg. 255, 109\u2013115. https:\/\/doi.org\/10.1097\/SLA.0b013e318238f461 (2012).","journal-title":"Ann. Surg."},{"key":"99359_CR27","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1200\/JCO.2011.36.1667","volume":"29","author":"BG Haffty","year":"2011","unstructured":"Haffty, B. G., Hunt, K. K., Harris, J. R. & Buchholz, T. A. Positive sentinel nodes without axillary dissection: Implications for the radiation oncologist. J. Clin. Oncol. 29, 4479\u20134481. https:\/\/doi.org\/10.1200\/JCO.2011.36.1667 (2011).","journal-title":"J. Clin. Oncol."},{"key":"99359_CR28","doi-asserted-by":"publisher","first-page":"830","DOI":"10.5858\/arpa.2015-0296-OA","volume":"140","author":"JA Bishop","year":"2016","unstructured":"Bishop, J. A., Sun, J., Ajkay, N. & Sanders, M. A. Decline in frozen section diagnosis for axillary sentinel lymph nodes as a result of the American College of Surgeons Oncology Group Z0011 trial. Arch. Pathol. Lab Med. 140, 830\u2013835. https:\/\/doi.org\/10.5858\/arpa.2015-0296-OA (2016).","journal-title":"Arch. Pathol. Lab Med."},{"key":"99359_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/ajcp\/aqw078","volume":"146","author":"JM Jorns","year":"2016","unstructured":"Jorns, J. M. & Kidwell, K. M. Sentinel lymph node frozen-section utilization declines after publication of American College of Surgeons Oncology Group Z0011 trial results with no change in subsequent surgery for axillary lymph node dissection. Am. J. Clin. Pathol. 146, 57\u201366. https:\/\/doi.org\/10.1093\/ajcp\/aqw078 (2016).","journal-title":"Am. J. Clin. Pathol."},{"key":"99359_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/tbj.12728","volume":"23","author":"MM Fillion","year":"2017","unstructured":"Fillion, M. M. et al. Healthcare costs reduced after incorporating the results of the American College of Surgeons Oncology Group Z0011 trial into clinical practice. Breast J. 23, 275\u2013281. https:\/\/doi.org\/10.1111\/tbj.12728 (2017).","journal-title":"Breast J."},{"key":"99359_CR31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1245\/s10434-012-2664-0","volume":"20","author":"MS Camp","year":"2013","unstructured":"Camp, M. S. et al. Application of ACOSOG Z0011 criteria reduces perioperative costs. Ann. Surg. Oncol. 20, 836\u2013841. https:\/\/doi.org\/10.1245\/s10434-012-2664-0 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"99359_CR32","doi-asserted-by":"publisher","first-page":"449","DOI":"10.4149\/neo_2018_170321N202","volume":"65","author":"T Nowikiewicz","year":"2018","unstructured":"Nowikiewicz, T. et al. The current application of ACOSOG Z0011 trial results: Is further implementation of sentinel lymph node intra-operative histopathological examination mandatory in breast cancer patients\u2014A single-centre analysis. Neoplasma 65, 449\u2013454. https:\/\/doi.org\/10.4149\/neo_2018_170321N202 (2018).","journal-title":"Neoplasma"},{"key":"99359_CR33","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.breast.2017.06.031","volume":"34","author":"MEM van der Noordaa","year":"2017","unstructured":"van der Noordaa, M. E. M., Vrancken Peeters, M. T. F. D. & Rutgers, E. J. T. The intraoperative assessment of sentinel nodes\u2014Standards and controversies. Breast 34, S64\u2013S69. https:\/\/doi.org\/10.1016\/j.breast.2017.06.031 (2017).","journal-title":"Breast"},{"key":"99359_CR34","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1245\/s10434-014-4090-y","volume":"22","author":"A Chung","year":"2015","unstructured":"Chung, A., Gangim, A., Mirocha, J. & Giuliano, A. Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery. Ann. Surg. Oncol. 22, 1128\u20131132. https:\/\/doi.org\/10.1245\/s10434-014-4090-y (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"99359_CR35","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s10147-018-1297-0","volume":"23","author":"N Kittaka","year":"2018","unstructured":"Kittaka, N. et al. A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery. Int. J. Clin. Oncol. 23, 860\u2013866. https:\/\/doi.org\/10.1007\/s10147-018-1297-0 (2018).","journal-title":"Int. J. Clin. Oncol."},{"key":"99359_CR36","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1111\/tbj.13851","volume":"26","author":"C Morigi","year":"2020","unstructured":"Morigi, C. et al. Feasibility and surgical impact of Z0011 trial criteria in a single-Institution practice. Breast J. 26, 1330\u20131336. https:\/\/doi.org\/10.1111\/tbj.13851 (2020).","journal-title":"Breast J."},{"key":"99359_CR37","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/cancers12040950","volume":"12","author":"J Jung","year":"2020","unstructured":"Jung, J. et al. Validating the ACOSOG Z0011 trial result: A population-based study using the SEER database. Cancers (Basel) 12, 950. https:\/\/doi.org\/10.3390\/cancers12040950 (2020).","journal-title":"Cancers (Basel)"},{"key":"99359_CR38","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/tbj.14191","volume":"27","author":"J Tseng","year":"2021","unstructured":"Tseng, J. et al. Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial. Breast J. 27, 216\u2013221. https:\/\/doi.org\/10.1111\/tbj.14191 (2021).","journal-title":"Breast J."},{"key":"99359_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/tbj.14140","volume":"27","author":"DV Peristeri","year":"2021","unstructured":"Peristeri, D. V. & Harissis, H. V. Axillary lymph node dissection vs sentinel biopsy only among women with early-stage breast cancer and sentinel node metastasis: A systematic review and meta-analysis. Breast J. 27, 158\u2013164. https:\/\/doi.org\/10.1111\/tbj.14140 (2021).","journal-title":"Breast J."},{"key":"99359_CR40","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1245\/s10434-020-08923-7","volume":"28","author":"TW Huang","year":"2021","unstructured":"Huang, T. W., Su, C. M. & Tam, K. W. Axillary management in women with early breast cancer and limited sentinel node metastasis: a systematic review and metaanalysis of real-world evidence in the post-ACOSOG Z0011 era [published correction appears in Ann Surg Oncol. 2020 Aug 10]. Ann. Surg. Oncol. 28, 920\u2013929. https:\/\/doi.org\/10.1245\/s10434-020-08923-7 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"99359_CR41","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1245\/s10434-020-08928-2","volume":"28","author":"MF Almahariq","year":"2021","unstructured":"Almahariq, M. F. et al. Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy. Ann. Surg. Oncol. 28, 930\u2013940. https:\/\/doi.org\/10.1245\/s10434-020-08928-2 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"99359_CR42","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1245\/s10434-014-3752-0","volume":"21","author":"J Gooch","year":"2014","unstructured":"Gooch, J. et al. The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1\u2013T2 breast cancer. Ann. Surg. Oncol. 21, 2897\u20132903. https:\/\/doi.org\/10.1245\/s10434-014-3752-0 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"99359_CR43","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamasurg.2015.1687","volume":"150","author":"AH Choi","year":"2015","unstructured":"Choi, A. H. et al. Size of extranodal extension on sentinel lymph node dissection in the American College of Surgeons Oncology Group Z0011 Trial Era. JAMA Surg. 150, 1141\u20131148. https:\/\/doi.org\/10.1001\/jamasurg.2015.1687 (2015).","journal-title":"JAMA Surg."},{"key":"99359_CR44","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1245\/s10434-019-08104-1","volume":"27","author":"AV Barrio","year":"2020","unstructured":"Barrio, A. V. et al. Microscopic extracapsular extension in sentinel lymph nodes does not mandate axillary dissection in Z0011-eligible patients. Ann. Surg. Oncol. 27, 1617\u20131624. https:\/\/doi.org\/10.1245\/s10434-019-08104-1 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"99359_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/SLA.0000000000002354","volume":"266","author":"M Morrow","year":"2017","unstructured":"Morrow, M. et al. Axillary dissection and nodal irradiation can be avoided for most node-positive Z0011-eligible breast cancers: A prospective validation study of 793 patients. Ann. Surg. 266, 457\u2013462. https:\/\/doi.org\/10.1097\/SLA.0000000000002354 (2017).","journal-title":"Ann. Surg."},{"key":"99359_CR46","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.clon.2015.07.005","volume":"27","author":"A Goyal","year":"2015","unstructured":"Goyal, A. & Dodwell, D. POSNOC: A randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin. Oncol. (R. Coll. Radiol.). 27, 692\u2013695. https:\/\/doi.org\/10.1016\/j.clon.2015.07.005 (2015).","journal-title":"Clin. Oncol. (R. Coll. Radiol.)."},{"key":"99359_CR47","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12885-017-3361-y","volume":"17","author":"J de Boniface","year":"2017","unstructured":"de Boniface, J. et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: The randomized controlled SENOMAC trial. BMC Cancer 17, 379. https:\/\/doi.org\/10.1186\/s12885-017-3361-y (2017).","journal-title":"BMC Cancer"},{"key":"99359_CR48","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1186\/s12885-018-5053-7","volume":"18","author":"G Houvenaeghel","year":"2018","unstructured":"Houvenaeghel, G. et al. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: Axillary dissection versus no axillary dissection in patients with involved sentinel node. BMC Cancer 18, 1153. https:\/\/doi.org\/10.1186\/s12885-018-5053-7 (2018).","journal-title":"BMC Cancer"},{"key":"99359_CR49","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13014-020-01672-7","volume":"15","author":"M Algara L\u00f3pez","year":"2020","unstructured":"Algara L\u00f3pez, M. et al. OPTimizing Irradiation through Molecular Assessment of Lymph node (OPTIMAL): A randomized open label trial. Radiat. Oncol. 15, 229. https:\/\/doi.org\/10.1186\/s13014-020-01672-7 (2020).","journal-title":"Radiat. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99359-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:17:03Z","timestamp":1670084223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99359-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99359"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99359-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19893"}}